ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 150 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $2,611,000 | -77.2% | 30,550 | -69.0% | 0.19% | -77.2% |
| Q2 2018 | $11,431,000 | +128.3% | 98,631 | +59.3% | 0.83% | +119.1% |
| Q1 2018 | $5,008,000 | +182.0% | 61,901 | +63.0% | 0.38% | +211.6% |
| Q3 2017 | $1,776,000 | +361.3% | 37,967 | +203.5% | 0.12% | +348.1% |
| Q1 2017 | $385,000 | +4.6% | 12,510 | -9.6% | 0.03% | 0.0% |
| Q3 2016 | $368,000 | -70.2% | 13,832 | -74.3% | 0.03% | -78.4% |
| Q3 2013 | $1,234,000 | – | 53,863 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
| Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
| Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
| Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
| Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
| ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
| Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
| Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |